Hemophilia presents with its own set of challenges when it comes to management. Extended half-life (EHL) recombinant factor VIII drugs promise excellent prophylaxis by reducing dose frequency, enhancing compliance, and improving quality of life while maintaining safety and efficacy. Join us live as Takeda presents a detailed overview of the rationale for Hemophilia management, role of EHL coagulation factors and their use in the treatment of haemophilia. 

Hemophilia Management: Role of EHLs in Prophylaxis

Extended half-life (EHL) recombinant factor VIII drugs promise excellent prophylaxis by reducing dose frequency, enhancing compliance, and improving quality of life while maintaining safety and efficacy. This session will provide a detailed overview of the rationale for developing EHL coagulation factors and their use in the treatment of haemophilia A, with a focus on the indications, efficacy, and safety of the existing EHL-FVIII products.

Dr. Sudhir Atri

2

348

5.7K

4.7

Sessions Taken

210

4.7

225

4.5